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Abstract This review discusses the most important current
methods employing mass spectrometry (MS) analysis for the
study of protein affinity interactions. The methods are
discussed in depth with particular reference to MS-based
approaches for analyzing protein–protein and protein–
immobilized ligand interactions, analyzed either directly or
indirectly. First, we introduce MS methods for the study of
intact protein complexes in the gas phase. Next, pull-down
methods for affinity-based analysis of protein–protein and
protein–immobilized ligand interactions are discussed.
Presently, this field of research is often called interactomics
or interaction proteomics. A slightly different approach that
will be discussed, chemical proteomics, allows one to analyze
selectivity profiles of ligands for multiple drug targets and off-
targets. Additionally, of particular interest is the use of surface
plasmon resonance technologies coupled with MS for the
study of protein interactions. The review addresses the
principle of each of the methods with a focus on recent
developments and the applicability to lead compound genera-
tion in drug discovery as well as the elucidation of protein
interactions involved in cellular processes. The review focuses
on the analysis of bioaffinity interactions of proteins with other
proteins and with ligands, where the proteins are considered as
the bioactives analyzed by MS.
Keywords Mass spectrometry. Protein–protein
interactions . Chemical proteomics . affinity. Native mass
spectrometry and interaction proteomics
Abbreviations
ADAP adhesion and degranulation promoting adapter
protein
CggR central glycolytic genes repressor
ESI electrospray ionization
FBP fructose 1,6-bisphosphate
GPCR G-protein-coupled receptor
His histidine
ICAT isotope-coded affinity tags
IMAC immobilized metal affinity chromatography
IMS ion mobility spectrometry
iTRAQ isobaric tags for relative and absolute quantitation
LC liquid chromatography
HSA human serum albumin
MALDI matrix-assisted laser desorption ionization
MS mass spectrometry
Nampt nicotinamide phosphoribosyltransferase
NMR nuclear magnetic resonance
PEBP phosphatidylethanolamine-binding protein
RXR retinoid X receptor
SILAC stable isotope labeling by amino acids in cell
culture
SPR surface plasmon resonance
TAP tandem affinity purification
Introduction
This review addresses mass spectrometry (MS) methods for
the study of (intact) protein complexes and so-called
protein–protein-interaction-based pull-down strategies to
elucidate these bioactive interactions. In addition, it
discusses automated digestion steps after affinity purifica-
tions and surface plasmon resonance technologies coupled
with MS. The methods described are used mainly in two
research areas. Firstly, they are used in fundamental studies
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of protein interactions with other proteins and with small
molecules [1]. This is an important research area aimed at
gaining a better understanding of biological processes in
general and more specifically their cellular processes.
Looking more elaborately at cellular processes, signaling
cascades involve many coordinated multiprotein binding
events, production and metabolism of signaling molecules,
modifications of proteins, and binding of small signaling
molecules to proteins [2]. These processes facilitate the
cellular machinery needed for homeostasis and, for example,
allow coordinated tissue growth. Furthermore, other
processes such as cellular localization of proteins and
cellular morphology processes are mediated by protein
binding events and are pivotal for cells and the functioning
of the body. Secondly, the study or screening of small
molecules that bind to proteins can also be used to screen for
hits or lead compounds in drug discovery. With the
emergence of protein–protein interactions and biopharma-
ceuticals in drug discovery and development, screening and
studying these interactions are becoming increasingly
important in this research area as well [3].
The different distinct MS approaches which are
discussed in this review are as follows. First, the study of
noncovalent complexes directly from solution by MS (native
MS). The second topic is the study of cellular protein
complexes involved in signaling events by pull-down
(“fishing”)-based interaction proteomics. Third, chemical
proteomics is looked at; this allows one to screen selectivity
profiles of ligands for multiple drug targets and off-targets.
Finally, surface plasmon resonance (SPR) coupled with MS
for protein affinity analysis, quantification, and identification
is discussed. Many reviews have been published about the
four distinct approaches that are discussed here. This review,
however, provides an overview of the different MS-based
approaches with recent examples and focuses on the protein
binding aspects and methods behind them in relation to
biological binding events and less on the MS technologies.
For every method, recent applications and specific examples
of studies performed are briefly discussed.
Electrospray ionization (ESI) and matrix-assisted laser
desorption ionization (MALDI) are the most suitable
methods for generating gas-phase ions of large biomole-
cules. In the case of ESI, many different intact noncovalent
protein complexes can be studied in the gas phase under
certain conditions. These studies are typically called native
MS studies. They also allow one to study protein–ligand
complexes (receptors as well as enzymes). Ganem et al. [4]
and Katta and Chait [5] were among the first to use ESI-MS
to study noncovalent receptor–ligand complexes and
biological myoglobin interactions. For the analysis of
noncovalent complexes by MS, a great variety of biological
interactions have been studied: receptor–ligand, enzyme–
substrate, DNA duplex and quadruplex species, intact
multimeric proteins, host–guest, oligonucleotide–ligand
and protein-ligand complexes, and protein–protein com-
plexes [5–14]. Even intact virus assemblies are currently
analyzed with native MS approaches [15].
The advantage of native MS for structural-biology-
oriented studies compared with other approaches, such as
crystallography, protein nuclear magnetic resonance (NMR)
and isothermal titration calorimetry, is the possibility to look
directly at protein–protein and protein–ligand interactions in
solution. This permits scientists to rapidly effectuate
changes (e.g., add ligand or protein) to the in vitro system
and thereby study directly the effects on the protein
complexes dynamically under real-time conditions. Also,
MS allows the study of extremely large protein complexes
and even virus assemblies, which is out of scope for, e.g.,
crystallography and protein NMR. Furthermore, for MS
approaches in the native MS area, only low amounts of
proteins are needed as they are commonly introduced via a
nano-ESI source. With sufficient analytical resolution, the
successful analysis of picomolar amounts of large heterog-
enous protein complexes becomes reality. In addition, it
allows real-time addition of cofactors, substrates, and
ligands while monitoring the resulting changes to the
complexes. This contrasts with the limited possibilities of
other methods used for analyzing the stoichiometry of
protein complexes, such as crystallography and protein
NMR. To obtain sufficient MS signals, however, high
protein concentrations (e.g., generally low micromolar
concentration range, while only consuming low volumes
introduced via nano-ESI capillaries) are required because
the overall MS signal is divided over isotopic patterns and
differently charged protein complexes.
The study of noncovalent complexes directly by MS
relies on extensive optimization to obtain sufficiently
stabile protein–protein or protein–ligand complexes in
solution and in the gas phase. Furthermore, for the study
of protein–ligand interactions it is mandatory to distinguish
the protein–ligand complex from the unbound protein
without a separation step. Presently, progress in the
development of MS and its application to protein analysis
in the gas-phase have led to major improvements in this
field. Also, these methods provide the most direct evidence
of protein–ligand and protein–protein complexation and
can be used as a model for in vivo complexation, with
the caveat that gas-phase complexation in the mass
spectrometer is a good representation of in vivo binding,
and is not an analytical artifact caused by the analysis
[16]. Contrary to ESI, MALDI techniques are less suited
for the study of noncovalent protein–protein and protein–
ligand interactions as these interactions are often disrupted
under the conditions needed and the procedures followed
to produce the MALDI matrix.
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A distinctly different way of analyzing protein–protein
interactions is performed indirectly after so-called pull-down
assays. For this, the protein (or ligand) of interest is
immobilized to create an affinity column in a manner similar
to that for affinity chromatography approaches. After all
bound proteins have been trapped and subsequently released,
MS analysis is often performed after a 1D gel electrophoresis
separation and a (tryptic) digestion of the separated proteins
[17]. Instead of a normal affinity-chromatography-based
protein complex purification, immunoprecipitation [18] or
tandem affinity purification [19] can be used. The protein-
“fishing”-based MS approaches discussed in this review are
not suited for the dynamic study of protein binding events,
but rather allow the identification of large multiprotein
complexes involving many different proteins.
Finally, SPR has been coupled with MS to study protein
binding events on an SPR chip directly followed by MS
identification of the bound proteins. This approach allows
protein quantification combined with structural character-
ization/identification of the proteins. Consequently, MS
complements the SPR detection and may reveal structural
modifications not detected by SPR [20].
The study of noncovalent complexes by native MS
Analysis of noncovalent complexes by MS, also known as
native MS, requires ESI-compatible buffer solutions. This
implies that in a number of cases maximum sensitivity is
not achieved and/or nonphysiological conditions have to be
used. Although noncovalent complexes observed by MS
are not analyzed directly from real cellular systems, most
often the stoichiometry of complexes determined by native
MS matches that determined in other ways, such as electron
microscopy, X-ray crystallography, and NMR. There are,
however, a few recognized exceptions [21].
In general, native MS is a very powerful technique for
the study of protein complexes, complementary to more
traditional approaches. Other approaches such as crystal-
lography and NMR have different analytical capabilities.
Whereas crystallography allows a detailed 3D image of a
protein–ligand complex to be obtained, the analysis of
multiprotein complexes, large protein complexes, and
several types of protein classes in general is difficult or
the protein complexes may be impossible to crystallize.
Furthermore, crystallography only permits the analysis of a
static crystal and real-life dynamic analysis in vitro is
therefore not possible. Protein NMR, on the other hand, is
an emerging technology but the study of large and complex
protein structures, such as whole virus assemblies, is still
not feasible. For protein NMR, protein sizes in the 0.1–1-
MDa range have been studied [22, 23]. With NMR studies,
homomeric complexes are analyzed more conveniently than
heteromeric protein complexes as the NMR spectra then
become much more difficult to interpret, which is not an
issue with native MS. Currently, among the largest protein
structures resolved by protein NMR are the 300-kDa
aspartate transcarbamoylase [24] and the 670-kDa protea-
some [23] obtained by the group of Kay. With native MS,
among the currently largest protein complexes (over 10
MDa) studied is the Norwalk virus assembly [15].
All technologies used to study protein complexes have
their own intrinsic advantages and disadvantages. In this
regard, MS allows the dynamic real-life study of protein
complexes, the study of very large complexes, and the
stoichiometric determination of the complexes analyzed,
and importantly only requires small amounts of protein. In
contrast, high-resolution 3D protein structures cannot be
determined by MS techniques.
Advances in MS, however, do provide new opportunities
regarding the analysis of these complexes. One can think of
advanced nano-ESI sources, new ionization techniques
such as ambient temperature ionization, and implementa-
tion of ion mobility spectrometry (IMS) technologies, but
also new and adapted MS configurations and hardware
[25]. Still, the buffers used for biochemical studies that
mimic physiological conditions often contain phosphates
and other nonvolatile salts [e.g., phosphate-buffered saline
or tris(hydroxymethyl)aminomethane buffer with NaCl]
and cannot be used in combination with ESI-MS because
they are nonvolatile. Also, the use of a low pH for efficient
ESI-MS in positive ionization mode is not an option when
studying biological noncovalent complexes, nor is the
commonly used high percentage of organic modifier.
Instead, physiological buffer conditions have to be substi-
tuted with MS-compatible buffers, such as ammonium
formate, acetate and bicarbonate. Furthermore, the percent-
age of methanol, acetonitrile, or 2-propanol has to be low
(usually lower than 5%) to prevent dissociation or
denaturation of the noncovalent complexes to be studied.
Finally, nonvolatile additives such as detergents and block-
ing reagents may cause ionization suppression, and their
use should be avoided or they should only be used in very
low concentrations. Another factor to take into account is
that the complexes that are formed and studied in native
MS depend on both protein–protein and protein–ligand
affinities and their concentrations. For most proteins (and
ligands), much higher concentrations have to be used than
those present under physiological conditions. Therefore,
one must be aware of the physiological relevance of the
complexes studied as in the body the concentrations of
proteins studied are much lower. This implies that low-
affinity protein complexes may be seen under the artificial
conditions with high protein concentrations in the mass
spectrometer, but might have less relevance in the body
(or only under specific conditions) when they are not
formed or are only formed at very low percentages.
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A way to study these possible effects might be by
analyzing the protein complexes in different ratios and
concentrations and by omitting specific binding partners.
Although analysis of the protein complexes in lower
concentrations will give a worse signal-to-noise ratio,
observed changes in the ratios of the complexes seen might
give indications of the affinities of the different binding
partners in these complexes. Also, chemical cross-linking at
lower protein concentrations followed by analysis of the
complexes under denaturing conditions can by utilized to
verify if the complexes are relevant at low concentration.
In-solution dissociation experiments can also give valuable
additional information about the binding interactions of the
interaction partners. Nonspecific oligomerization, for
example, can be distinguished from specific interactions
by looking at the distribution of the molecules, which is
related to the initial concentration and droplet sizes in the
ESI source [26]. All these considerations dictate the balance
required between efficient and representative analyses.
ESI-MS can be seen as a complementary tool to
established biochemical methods for investigating protein
structure and conformation under nondenaturating condi-
tions. Types of information that can be obtained by ESI-MS
include protein conformation properties and molecular
interactions, protein–protein interactions, protein–ligand
interactions, and protein–cofactor interactions. Some typical
examples are now briefly discussed.
Noncovalent interactions between low molecular weight
antiamyloid agents and amyloid β peptides were studied
by Martineau et al. [27] to rank binders that may be able to
modulate/inhibit the amyloid β aggregation process.
Jecklin et al. [28] compared different approaches, ESI-
MS, SPR, and isothermal titration calorimetry, for label-
free quantitative assessment of binding strengths of the
protein human carbonic anhydrase I with small ligands.
Real-time monitoring of enzymatic conversions and inhi-
bition and formation of complexes is also possible with
MS [29]. Hydrogen–deuterium exchange experiments can
be used to study proteins by MS and allow one to monitor
protein dynamics and binding interactions over time [30].
Bich et al. [31] applied MS to study the retinoic acid
induced heterodimerization of the nuclear retinoid X
receptor (RXR), resulting in formation of an activated
dimer that binds to DNA hormone response elements,
mimicked by DNA-based direct repeat configurations. This
is exemplified in Fig. 1. The dots in the MS spectrum
represent the m/z values of the differentially charged ions
corresponding to the complex of the RXR–retinoic acid
receptor dimer bound to the double-helix DNA fragment
DR5. The dots on top of the peaks represent the same ions
with different charge states. After cross-linking, the authors
also successfully studied these complexes with high-mass
MALDI-MS. Van Duijn et al. [12] have used native MS for
the analysis of complexes involved in the chaperonin-assisted
refolding of the major capsid protein (gp23) of bacteriophage
T4. Intermediate complexes that are involved in chaperonin
(GroEL-GroES) folding were studied as such. It was found
that chaperonin complexes can bind up to two unfolded gp23
proteins. When in complex with the cochaperonin gp31, only
one gp23 can bind. Figure 2 shows typical results obtained
for this study. Ions with different charge states corresponding
to the 801-kDa complex (GroEL; blue dots), the 857-kDa
complex (one gp23 molecule bound to GroEL; yellow dots),
and the 913-kDa complex (two gp23 molecules bound to
GroEL; red dots) are seen in Fig. 2a. Figure 2b shows the
deconvoluted spectrum of the three different complexes.
These results nicely illustrate the capabilities of native MS
for the study of protein–protein interactions.
Following the advent of native MS, very large protein
complexes such as ribosomes and even whole viruses can
now be studied in the gas phase [32–34]. With the recent
addition of ion mobility to MS analysis, new doors have
been opened for the study of such large complexes [35]. In
IMS, biomolecules and noncovalent complexes are sepa-
rated in the gas phase according to their differences in size,
shape, and charge prior to actual MS analysis. For IMS,
new possibilities lie, for example, in the analysis of
heterogeneous protein complexes, providing information
on the topology, stoichiometry, and cross section. This new
Fig. 1 Interaction of the nuclear hormone receptor dimer retinoic acid
receptor (RAR) − retinoid X receptor (RXR) binding to a short strand
of DNA (induced by retinoic acid binding). All RXR heterodimers
preferentially bind DNA at two sites of a direct repeat (DR)
configuration, separated by one to five nucleic acids, called DR1,
DR2, DR3, DR4, and DR5. The binding to a DR5 configuration is
shown, resembling binding to hormone response elements (HREs).
Upon binding to actual HREs, gene transcription can occur. (Reprinted
from Bich et al. [31]. With permission)
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addition to the available MS tools does, however, require
additional and extensive data handling to have feasible data
interpretation [36]. Research has already shown that results
obtained by IMS-MS for noncovalent complexes show
good correlation with results obtained by traditionally
applied methods, such as cryoelectron microscopy and
X-ray crystallography [37]. However, there is also evidence
that proteins and protein complexes may become more
compact or collapse in the gas phase in the absence of water
[38]. Besides the technologies mentioned, electron micros-
copy is an alternative method to MS to look at protein
complexes, and also protein complexes consisting of many
different proteins, provided that the complexes are very
large [39]. With crystallography approaches, often ligand
binding to a receptor or enzyme is studied.
A selected set of very recent typical examples of studies
involving native MS are now discussed. By combining IMS-
MS with tandem MS, one can characterize non-covalently
bound macromolecular complexes (mass, cross-sectional
area, and stability) with only one experiment, which was
demonstrated by Knapman et al. [40] by determining the
topology of virus assembly intermediates. Boeri-Erba et al.
[41] used IMS-MS to study the influence of subunit packing
and the charge on the dissociation of multiprotein complexes
of heat shock protein 16.9 and stable protein 1. Also, native
MS can be used to identify protein aggregates after (size-
exclusion) chromatography, which was demonstrated for
human monoclonal antibody aggregates [42]. Recent advances
in native MS, including specifically applied surface-induced
dissociation approaches, allow one to get a closer look at
quaternary structures of protein complexes [43]. The central
glycolytic genes repressor (CggR) plays a role in glycolysis in
Bacillus subtilis. The effector sugar fructose 1,6-bisphosphate
(FBP) abolishes binding cooperativity of CggR and DNA.
Atmanene et al. [44] used native MS to investigate FBP-
dependent CggR–DNA interactions using automated chip-
based nano-ESI MS and traveling wave IMS-MS. Among
others findings, it was revealed that tetrameric CggR
dissociates into dimers upon FBP binding. In a more
recent study, the assembly states of the nucleosome
assembly protein 1 were studied by sedimentation velocity
and nativeMS [45]. From this it was concluded that the basic
assembly was a dimer from which even-numbered higher-
assembly states formed. Phosphatidylethanolamine-binding
protein (PEBP) can be associated with morphine and
morphine glucoronides. In a native MS study, Atmanene
et al. [46] characterized these interactions and finally
suggested that PEBP might protect morphine 6-glucuronide
following its secretion into blood, which leads to a longer
half-life. The ribosomal stalk complex has a role in the
delivery of translation factors to the ribosome. The stoichi-
ometry of these complexes is important to further understand
their functioning, which was investigated by Gordiyenko
et al. [47].
The study of cellular protein complexes involved in signaling
events with pull-down-based interaction proteomics
For many drug target systems, genomics approaches, e.g.,
by RNA array analysis of gene expression, have revealed
Fig. 2 Typical native mass spectrometry (MS) results from van Duijn
et al. [12] a Nano-electrospray ionization mass spectrum of a mixture
of GroEL and unfolded polypeptide gp23 (1:4). Charge-state series of
GroEL (800 kDa; blue circles), one gp23 molecule bound to GroEL
(856 kDa; yellow circles) and two gp23 molecules bound to GroEL
(912 kDa; magenta circles) are seen. b The corresponding deconvo-
luted spectrum, which reveals the three chaperonin complexes with
their binding stoichiometries. (Reprinted from van Duijn et al. [12].
With permission)
Studying protein affinity with MS 1113
that receptor stimulation results in numerous pathway
regulations. More recent advances in proteomics also allow
not only the unraveling of the complex protein regulations
mediated by ligand signaling, but moreover give insights
into protein phosphorylation processes that precede this.
These processes are efficiently studied with, e.g., phospho-
proteomics approaches based on phosphopeptide purifica-
tion with affinity chromatography [with, e.g., immobilized
metal affinity chromatography (IMAC) or TiO2] performed
after proteolytic digestion of all proteins. The affinity-
purified phosphopeptides are then separated by liquid
chromatography (LC) and analyzed by MS [48].
We are starting to understand that ligand-mediated
signaling is not a one-directional linear process, but rather
a parallel process with different dependent, independent,
cross-linking, correlating, and influencing pathways and
eventual effects [49–51]. Protein kinases play pivotal roles
in transmitting ligand-mediated signals through many
different pathways. Before eventual gene expression in
cells takes place, phosphorylation and dephosphorylation
steps of subsequent protein kinases and other proteins
occur, thereby activating and/or deactivating them, in order
to pass on signaling events. Also, protein localization
processes, e.g., based on phosphorylation state, are impor-
tant mediators in (localized) cellular processes. Finally, key
proteins in different pathways are upregulated or down-
regulated and dictate the final cellular (desired or unde-
sired) effects. Through all these signaling cascades, protein
complexes play crucial roles. In other words, the way that
proteins interact with each other, form noncovalent com-
plexes, and localize, internalize, and recruit other proteins is
fundamental to cellular signaling [49, 52, 53]. Some typical
examples include G-protein-(in)dependent and/or β-arrestin
signaling for G-protein-coupled receptors (GPCRs), coac-
tivator and/or repressor protein recruitment for the nuclear
receptors, and localization of certain proteins (e.g., protein
kinases and GPCRs) by binding/complexation to/with, e.g.,
anchoring proteins [50, 51, 54–57]. These important
processes in signaling are difficult to study with traditional
biological/biochemical approaches as they comprise a
complex interplay of many different events. One relatively
new way of studying these complexes in a more compre-
hensive manner is by interactome proteomics.
In interactome proteomics, an affinity purification of the
protein complexes to be studied precedes the actual
analysis. The affinity purification uses the key interactor
to be studied for its interactome in a relevant biological
surrounding. Here, the key interactor can be a ligand, an
inhibitor, a protein, DNA, RNA, or another biomolecule,
whereas the biological surroundings are often lysates of
(cultured) cells, but also tissues, subcellular compartments,
organs, and insects have been studied this way. The key
interactor is immobilized onto a solid support, such as a
(spin) affinity column or (magnetic) beads. When the key
interactor is incubated with the lysate, complexes are
formed with the key interactor under the conditions used
for the study, thereby selectively extracting or “fishing” the
interacting proteins from the complex mixture. Figure 3
gives an overview of a typical interaction proteomics
workflow. The exemplary procedure depicted starts with
an affinity purification step (2a and 2b) of the sample (1a)
and the control (1b). After the affinity purification, the
proteins bound are separated on a gel (3a and 3b). The two
experiments can be performed in one experiment if, e.g., a
stable isotope labeling with amino acids in cell culture
(SILAC) is used. Subsequently, protein bands are excised
and digested in-gel. Then, MS-based analysis occurs. In the
example shown, nano-LC-MS is used for peptide separation
and analysis. This approach is essentially based on the
reversed principle of affinity-selection MS approaches
discussed by Jonker et al. [58]: Rather than immobilizing
the target proteins to retain ligands, one immobilizes the
ligands to retain the target proteins. Subsequent washing
away of all nonbinding entities (e.g., proteins, membranes,
and small molecules) followed by release of all binding
proteins (by, e.g., heat shock, pH shock, chaotropic agents,
organic modifiers, ligand-based displacement, or tryptic
digestion when a bottom-up approach is used) allows the
proteomic analysis of the interactome. Here it is mandatory
that the cell lysate used is carefully prepared in order to
maintain the cellular conditions in terms of the interactome/
noncovalent complexes under study. Cellular conditions or
cell-mimicking conditions are easily disturbed chemically
by buffer conditions/lysis conditions, as well as biologically
and are cell-mediated during the initiation of, e.g., cell lysis.
Furthermore, often cellular conditions are unknown (and
cannot be specified for different cell compartments) and
thus it is difficult to mimic them. The use of homogenized
tissues or even whole organs can be problematic. First, to
investigate cellular pathways it is important to know the
corresponding type of cell to which the proteins belong. An
association of different cell types should only be used to
give the first hints. Furthermore, if different cell types are
used in one batch, uncontrolled reactions may be initiated.
It is difficult to control changes occurring when only one
type of cell is homogenized because cell compartments are
destroyed. For example, disrupting the vacuole might cause
significant artefacts in the study of plant cells.
Alternatively, immunoprecipitation can be performed
instead of interactome fishing with immobilized key
interactors. An advantage of immunoprecipitation is the
possibility of in-solution incubation, which can avoid steric
hindrance of (co-)binders to the complexes formed with the
key interactor when it is not immobilized (the indirect
approach). A limitation is that the method depends on the
specificity of the antibodies used, the choice of the antigen,
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and the accessibility of the antibodies for binding the
antigens when the complexes are formed in solution.
With interactome proteomics, a control experiment is often
compared with the actual experiment in which the biological
matrix under study is stimulated by a certain chemical,
biological, or physical stimulus. For this approach, both
biological matrixes can be isotopically labeled. Although this
is an elegant way of incorporating the control experiment and
stimulated experiment in one analysis with a labeling
approach, controls can be performed without isotopic
labeling. The advantage of labeling is that both the control
and the stimulated experiments can be pooled and analyzed
in one simultaneous proteomics experiment where the
peptide ratios used to calculate protein ratios can be
distinguished in MS owing to the differences in molecular
masses between the differently labeled peptides. Labeling
can be achieved in situ during cell growth via SILAC for
proteomic comparison of the stimulus’ effect later on [59,
60]. Other applicable labeling approaches can be per-
formed, such as isobaric tags for relative and absolute
quantitation (iTRAQ; based on a combination of 18O, 15N,
and 13C to achieve isobars) [61], isotope-coded affinity
tags (ICAT) [62], labeling with 18O [63], and [2H6]
dimethyl labeling [64]. These labeling approaches have to
be performed after the interactome fishing process, that is,
after or during a digestion step of the isolated proteins, in
contrast to SILAC. The actual proteomics experiment can
be performed in a bottom-up approach in which first all
proteins are digested, followed by LC-MS analysis and
database searching [48]. The common approach involves
protein separation by 1D sodium dodecyl sulfate–
polyacrylamide gel electrophoresis. Here, gel bands are
subsequently excised, in-gel digested, and the peptides
formed are then analyzed by LC-MS (or potentially
MALDI-MS). An advantage of this approach is the
possibility for additional Western blotting for confirmation
of the identity of specific proteins. Also the molecular
mass of the excised proteins in denaturating gels can be
estimated, thus yielding additional confirmation. A disad-
vantage is that this method is quite labor-intensive.
An example of a typical pull-down proteomics study
involves the use of an immobilized inhibitor for phosphodi-
Fig. 3 Pull-down proteomics,
interactomics, or interaction
proteomics. The typical
workflow is illustrated. The
sample to be analyzed (1a) and
often a control sample (1b) are
subjected to affinity chromatog-
raphy (2a and 2b). Alternatively,
immunoprecipitation can also be
used (not shown). After
trapping, all bound proteins are
eluted (by, e.g., disruption or
sequential elution with affinity
displacers) and (often) subjected
to gel electrophoresis (3a and
3b). Sample and control proteins
are compared and all (or only
interesting) proteins are excised
from the gel slab, and are in-gel
digested (in gel bands) (4). The
resulting peptides can then be
separated by (nano)-liquid
chromatography (LC) (6) and
detected by MS (7). Alterna-
tively, matrix-assisted laser
desorption ionization MS may
also be used. The resulting total
ion current of a chromatogram
(8), the MS spectrum of a
peptide (9), the MS/MS
spectrum of the fragmented
peptide (10), and a database
search (11) are shown
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esterase 5 to study its interactome [65]. To gain specificity,
selective precleaning and elution protocols were developed
for efficient discrimination between specific and nonspecific
or less-specific binding proteins. A similar approach was
used with cyclic AMP affinity column materials to study a
specific protein kinase anchoring protein for type I cyclic
AMP dependency [66]. This protein plays important roles in
localization processes for specific kinases during complex
interplays of signaling events. For studying protein–protein
complexes, a method was developed in which the “bait
protein” was constructed as a glutathione S-transferase
fusion protein for interactome pull-down chromatography
with glutathione beads. These pull downs can be envisioned
as the protein-based version of yeast two-hybrid screens
[67]. Prior to eventual MS analysis and data handling for
protein identification, different sample preparations of
interacting proteins (e.g., specialized gel staining techniques
and in-gel tryptic digestions) were evaluated and used. An
example of immunoprecipitation pull downs is given for
GTP cyclohydrolase I, which is an important enzyme in the
biosynthesis of tetrahydrobiopterin, an essential cofactor for
aromatic amino acid hydroxylase and nitric oxide synthase
[68]. It was found that 29 proteins from different subcellular
components interacted with GTP cyclohydrolase I. In an
example where affinity protein columns were manufactured
for the pull down, proteins targeted by the thioredoxin
superfamily in Plasmodium falciparum were identified,
yielding 21 potential target proteins [69]. Another example
targeted the phosphatidylinositol 3,4,5-trisphosphate inter-
actome [70], important in regulations of cell physiological
processes, e.g., via GPCR-mediated signaling. In this study,
282 proteins were found to directly or indirectly interact
with phosphatidylinositol 3,4,5-trisphosphate.
The family of 14-3-3 proteins are regulatory proteins
conserved across species with the ability to bind many
different proteins involved in signaling, such as kinases and
membrane receptors. The importance of these proteins in
signaling processes renders them excellent candidates for
interactomics studies helping to unravel their exact binding
partners. This is true not only for mammalian 14-3-3
proteins, but also for plant proteins. Paul et al. [71] studied
Arabidopsis 14-3-3 complexes, which revealed highly
conserved interactions between humans and plants. Among
other important proteins, also in plants, are the protein
kinases. One study focused on transgenic rice plants to
identify binders to rice-leaf-expressed protein kinases fused
to tandem affinity purification (TAP) tags [19]. TAPs are
two-step affinity purification protocols which allow isola-
tion of protein complexes under close-to-physiological
conditions with the help of fusion proteins. These fusion
proteins can have a “bait” part, an enzymatic cleavage
part, and a trapping part, for example, protein A which
binds to immobilized IgG. After initial purification, the
TAP tag can be broken enzymatically for further process-
ing and eventual MS analysis. One manner of efficient
quantification of proteins after affinity trapping procedures
is the recently developed quantitative bacterial artificial
chromosomes interactomics [72]. In this approach, tagged
full-length baits are employed which are expressed under
endogenous control. Different cell lines with tagged
proteins are available for this approach. Actual quantifi-
cation occurs by SILAC, but it can also be performed by a
label-free approach.
The α7 nicotinic receptor, which is an important
potential drug target against several brain-residing diseases,
has also been studied indirectly with an interactomics
approach. Bungarotoxin, which has a high affinity for this
nicotinic receptor, was used as a key binding partner. For
this, isolated carbachol-sensitive α-bungarotoxin-binding
complexes from total mouse brain tissue were selectively
eluted and analyzed [73]. By comparison of results
obtained from wild-type mice and from α7 nicotinic
receptor knockout mice, binding proteins were identified
from the brain tissues used.
The importance of interactomics studies in life science
today is reflected by the many different studies performed
to investigate the binding partners of specifically selected
interaction proteins. Other recent examples include an
interactomics study towards the most widely expressed
isoforms of p63, a transcription factor for the p53 tumor
suppression protein [74]. Relevant binding partners of
helicases, which are important in the unwinding of the
strands of DNA double helixes, have been studied by
Jessulat et al. [75] by a TAP approach in an in vivo study.
Another TAP approach, by Guo et al. [76], centered on the
identification of human tuberous sclerosis protein 1 com-
plexes. In the case of binding partners of the estrogen
receptor as a key mediator in certain breast cancer cells,
knowledge of binding partners of the ligand-activated
receptor is important for a better understanding of trans-
duction of the hormonal signal that allows the cancer cells
to grow. These binding partners were revealed in an
interaction proteomics study using TAP by Tarallo et al.
[77]. Integrins are transmembrane proteins that are involved
in regulation of cellular mobility, shape, and cell cycle
processes. To look closely at associated proteins that might
be involved in these processes, Raab et al. [78] looked at
the interactome of the platelet integrin αIIb regulatory motif.
The use of tethered RNAs to detect RNA–protein inter-
actions was described by Lioka et al. [79], revealing
specific protein binders. The nuclear lamina is among other
factors an important regulator of the structural integrity of
the nucleus. It is involved in nuclear processes, including
DNA replication. Unraveling of binding partners of the
lamina can allow scientists to further understand the
processes behind the regulations involved. For this, protein
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interactors with lamin A and progerin were studied by
Kubben et al. [80]. The immune adapter protein adhesion
and degranulation promoting adapter protein (ADAP) is
involved in integrin-dependent migration and adhesion
processes after T-cell stimulation. To investigate and
differentiate between phosphorylation-specific and nonspe-
cific protein interactions, Lange et al. [81] used SILAC and
enzymatic 18O-labeling to identify ADAP interaction
partners. Jäger et al. [82] described an affinity purification
method to characterize HIV protein complexes. The
interaction partners of dysferlin, an important protein
involved in muscle membrane repair, were recently also
studied [83]. It was shown that dysferlin is not only
involved in membrane repair, but that it is also important
for maintenance and integrity of muscle membranes. For
proteins that interact with muscarinic receptor, Borroto-
Escuela et al. [84] revealed many protein interactions in
various signaling pathways that will allow a better
understanding of the muscarinic interactome.
An alternative, attractive approach uses protein trapping
with reactive chemical affinity tags which efficiently traps
proteins for MS-based analysis. Fischer et al. [85] and Luo
et al. [86] used this so-called capture compound MS
approach which involves binding of a small reactive
molecule (e.g., a druglike compound) to interacting proteins
followed by covalent reaction (e.g., after photoactivation)
with the binding proteins. An incorporated biotin function
then allows selective purification for MS analysis. In a
typical example, the broad-range and high-affinity protein
kinase binder staurosporine was used to trap and study
protein kinases in the hepatocyte cell line HepG2 [87]. To
study chemical cross-linking of covalently connected
binding partners in order to allow identification of interacting
proteins directly in cells, Sinz [88] discussed different in vivo
cross-linking strategies that allow protein–protein interac-
tions to be looked at under physiological conditions. Other
capture compound MS approaches include the profiling of
methyltransferases and S-adenosyl-L-homocysteine-binding
proteins [89] and the use of a genetically incorporated photo-
cross-linkable amino acid to study protein complexes of
protein 2 bound to mammalian growth factor receptor [90].
Chemical proteomics to screen selectivity profiles
of ligands for multiple drug targets and off-targets
Affinity beads or columns can be used in a more pharmaceu-
tically oriented fashion than interactome proteomics. Here, an
additional step is included involving the addition of different
concentrations of a ligand (e.g., lead compound) to cell
lysates prior to processing. This technology is the so-called
chemical proteomics approach [91]. Figure 4 gives an
overview of a typical chemical proteomics approach. In
the exemplary figure, Petri dishes with cells are shown (1a,
1b, 1c, and 1d), each incubated with a different stimulus
(different ligand concentrations in this case). After cell lysis
and sample preparation, the lysed cells are incubated with
affinity beads. The proteins bound for each incubation
(2a-d) are subsequently isolated by washing the beads (3 to
4) followed by elution with help of, e.g., a disruption step
(5a to 5b). Different approaches for protein separation can
be used prior to analysis (10a to 10b, or potentially 11a to
11b). iTRAQ labeling is performed, allowing the different
experiments (1a, 1b, 1c, and 1d) to be combined after
digestion and labeling. With this approach, the samples can
then be pooled prior to LC-MS analysis (9). The technology
uses affinity beads with immobilized ligand to fish out target
proteins for MS-based analysis. By addition of solution-
phase test ligands of pharmaceutical interest (which bind
with different affinities to the target proteins), the target
proteins, when bound to the test ligands, do not bind
anymore or bind in a lower percentage to the beads,
depending on their intrinsic test ligand affinities. For
specific interactions, this results in a reduced amount of
target protein extracted and consequently lower amounts
quantified per target protein by MS. Using this approach,
proteins complexing with the target proteins bound are not
looked at, but can theoretically be looked at if desired.
Awell-known example uses affinity beads (Kinobeads)
that are able to trap most, if not all, protein kinases via
their binding pocket(s) [92]. The approach uses immobi-
lized broad-selectivity kinase inhibitors that bind protein
kinases (and related proteins) mainly at their ATP binding
sites and related sites. In the presence of increasing
concentrations of a ligand, the ligand and the affinity
material compete for a binding site on the protein kinases
present in cellular lysates. This means that at low ligand
concentrations, only the high-affinity-binding kinases are
not trapped on the affinity material anymore as they are
bound to the ligand, whereas at higher ligand concen-
trations, also the lower-affinity kinases are unable to bind
to the affinity material anymore. Experiments with different
ligand concentrations are done and after pull downs followed
by proteomics analysis, decreasing amounts of affinity-
material-trapped kinases are detected with increasing ligand
concentrations. This is used to construct typical IC50 dose–
response curves for all kinases studied (up to hundreds at
once). There are 518 human protein kinases, and all protein
kinases that bind can theoretically be detected as can other
proteins that interact with the affinity material. Of course,
their individual cellular concentrations and activation states
in specific cell types might prevent binding and/or detection.
For this specific process, medically interesting target cells are
used where the endogenous protein kinases are the target
proteins. After lysis, the ligand is added, followed by affinity
trapping of the protein kinases, washing steps, release and
digestion of the protein kinases, labeling, and finally LC-MS.
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An iTRAQ labeling reagent is commonly used for this [92,
93]. The method also allows for measurement of ligand-
induced changes in phosphorylation states of the isolated
protein kinases. The main advantage of this method is that it
is capable of analyzing inhibitory panel profiles of protein
targets instead of aiming at a single drug target. This
possibility allows drug discovery projects to start aiming at
drugs capable of selectively inhibiting several drug targets in
a panel fashion. One challenge in protein kinase affinity
screening is that the most interesting selective inhibitors for
protein kinases are expected to bind allosterically (at non-
ATP binding sites) and consequently might not be detected.
These methods, however, are also starting to aim more
specifically at multiple binding sites.
To give one example, a quantitative chemical proteomics
approach was used to study the effects of small molecule
ABL kinase inhibitor drugs on hundreds of endogenously
expressed protein kinases and purine-binding proteins [92].
Furthermore, drug-induced changes in the captured pro-
teome’s phosphorylation state were also looked at. Typical
results obtained are shown in Fig. 5. Figure 5a shows
cultured cells with different chemical stimuli (ligands; in
this case drugs) at the top, and below this the schematic
process of binding of protein kinases to the affinity beads in
the presence of different concentrations of ligand is
depicted. The MS/MS spectrum at the bottom left of Fig.5a
shows the four characteristic iTRAQ reporter signals
indicative of the relative amount of protein kinase trapped
Fig. 4 Chemical proteomics.
The typical workflow is shown.
The sample with different con-
centrations of the test ligand
(four concentrations; 1a, 1b, 1c,
and 1d) are subjected to lysates
of cultured cells of interest and
incubated with immobilized
ligand affinity beads (2a-d).
After incubation (3), the affinity
beads with bound target proteins
are removed from the incubation
(4), washed, resuspended (5a),
and finally a disruption step (5b)
releases the bound target
proteins from the beads. The
crude protein mixtures are then
prepared for 1D (10a) or poten-
tially 2D (11a) gel electrophore-
sis followed by excision of the
proteins (10b, 11b). The proteins
can then be in-gel digested prior
to analysis. Alternatively,
proteins can be directly prepared
for digestion (6), digested (7 and
8) and subsequently labeled
with, e.g., isobaric tags for
relative and absolute quantita-
tion (iTRAQ). After iTRAQ
labeling, samples are combined
for straightforward eventual
relative protein quantification
from MS/MS spectra (see
Fig. 5) obtained by LC-MS/MS
analysis (9)
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and thus of the percentage of ligand binding to the respective
protein kinase. Shown at the bottom right of Fig. 5a are
schematic binding curves of four different protein kinases
(for which the ligand has no affinity for one protein kinase).
Figure 5b shows 16 graphs, showing the results for one typical
protein kinase per graph, with each graph having three actual
binding curves for the same three different drugs: bosutinib,
dasatinib, and imatinib. The bars in Fig. 5c represent relative
affinities of each protein kinase for the three drugs. Similar
work by Sharma et al. [94]described the analysis of small-
molecule kinase inhibitors, an antibody, and a tyrosine-
phosphorylated peptide as inhibitors of panels of protein
kinases. As inhibitors of protein kinases are used as research
tools in elucidating signal transduction cascades, characteriz-
ing these inhibitory profiles with chemical proteomics
approaches can also aid progress in fundamental research.
Finally, three very recent examples of typical chemical
proteomics studies are discussed. Rix et al. [95] used
chemical proteomics to study the binding kinases of BCR-
ABL kinase inhibitor INNO-406 in myeloid leukemia cells.
Better knowledge of its full target spectrum can help predict
side effects and novel treatment applications, and can
possibly provide information for next-generation therapies
involving kinase inhibitors.
CB30865 is a selective and potent cytotoxic agent of
previously unknown action mechanism. Chemical proteomics
revealed that its cytotoxicity is due to high-affinity inhibition
of nicotinamide phosphoribosyltransferase (Nampt) [96]. As
cancer cells develop dependence on Nampt, because of an
elevated energy requirement (involving NAD-consuming
enzymes), it was implied that Nampt-inhibiting molecules
provide a starting point for drug discovery with Nampt as a
potential target in cancer therapy.
Lastly, in a chemical proteomics approach an affinity
matrix was made from antiresorptive 5-chloro-1-(2,6-
dimethylpiperidin-1-yl)-N-tosylpentan-1-imine, where
prohibitin was identified as strong binding protein [97].
This might provide new handles for drug discovery aimed
at antiresorptive drugs.
Where most proteomics approaches use off-line digestion
steps, efforts to automate these have been made. In these
experiments, (online) affinity protein purification followed by
elution to online digestion reactors/chambers and finally
elution of the peptides formed to MS or LC-MS can form
fully automated analytical systems. This technique, however,
has not gained widespread use, probably owing to compati-
bility problems between conditions needed for affinity
purification, digestion, and (LC-)MS analysis, and the short
digestion times required. This review briefly discusses a few
selected examples.
A schematic view of an exemplifying setup used for
used for online affinity trapping of proteins followed by
in-solution online digestion and again trapping on a solid-
phase extraction column prior to LC-MS is depicted in
Fig. 6. In the complete setup, proteins are applied to
immunoaffinity chromatography. Bound proteins are sub-
sequently disrupted and eluted to an online bioreactor based
on continuous-flow protein digestion with a protease.
Peptides formed are subsequently trapped on a solid-phase
extraction column. After desalination, the trapped peptides
are subjected to LC-MS analysis, and the rest of the system
is reequilibrated for the next run. Hoos et al. [98]
accomplished successful online immunoaffinity chromatog-
raphy with human serum albumin (HSA) antibodies and
chemically adducted HSA followed by use of a solution-
phase digestion chamber, after which the samples were
analyzed online by LC-MS analysis. This technology was
capable of detecting reactive chemical agents or drugs able
to covalently bind to the cysteine-34 residue of HSAvia the
respective adducted peptide analyzed after digestion.
Another example includes the selective analysis of
online-immunoaffinity-purified cytochrome c [99]. A
slightly different technique can allow detection of proteins
with large similarities, such as polymorphic proteins or
proteins with different posttranslational modifications,
when an initial protein separation step is incorporated
[100]. With use of this method, proteins are first separated
by nano-LC prior to postcolumn online digestion and MS
analysis. Similar results were obtained with a method based
on column-switching recycling size-exclusion chromatog-
raphy, microenzymatic online digestion, and LC-MS [101].
The complexity of automation and/or the lack of
sensitivity are still serious drawbacks in these methods.
They can function efficiently, however, when the number of
proteins to be analyzed is limited. For the online digestion
part only, however, many different setups have been
developed [102–104]. Furthermore, also microfluidics
on-chip [105, 106], on-capillary zone electrophoresis
[107], and monolithic disk or bioreactor [108, 109]
digestion procedures after affinity-capturing are entering
the affinity screening arena. The development of a
Sepharose material with a small immobilized peptide for
metalloprotease selection based on affinity by Freije and
Bischoff [110] allowed sample enrichment in online
bioaffinity selection–trypsin digestion–MS proteomics in
order to identify proteases and rank affinities [111].
IMAC comprises different methods that are similar to
protein affinity chromatography. The main difference is that
IMAC separates proteins, small organic ligands, or phos-
phopeptides on the basis of their affinity for the immobi-
lized metal ion. This separation then depends on the
number and location of histidine (His) residues in proteins,
and cysteine and tryptophan residues to a lesser extent
[112]. For the already briefly discussed phosphoproteomics
approaches (see “The study of cellular protein complexes
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involved in signaling events with pull-down-based interaction
proteomics”), the affinity interaction is between the phosphate
group of phosphopeptides (which are formed after a
bottom-up digestion step) and the affinity material. For
His-tagged proteins, a very high affinity between the His-tag
and the immobilized metal ion efficiently traps them from any
matrix. For this reason, IMAC is the most widely usedmethod
for purification of proteins. Recently, Cheeks et al. [113]
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demonstrated a monolithic IMAC column for purification of
His-tagged lentiviral vectors, and Zhang et al. [114] used a
so-called affinity peptidomics method to affinity-capture
bioactive proteins or peptides on hydrogels and microarrays
followed by MALDI-MS for identification of the endoge-
nous peptides trapped or the proteolytic peptides that result
from trapped proteins. Because the IMAC affinity interaction
is not based on biological affinity interactions, it will not be
discussed further. By “biological affinity,” binding of ligands
or proteins to specific binding sites or pockets present in
target proteins (e.g., receptors or enzymes) is meant.
SPR coupled with MS for protein affinity analysis,
quantification, and identification
SPR biosensors consist of a prism against a thin metal layer
(e.g., gold) and a flow-through chamber containing analyte
solution at the opposite side of the metal layer. Surface
plasmons occurring at the metal–solution interface have a
certain wave vector, which depends on the structure and
composition of the metal surface and of the solution and
analytes near the surface. A light beam directed at the prism
undergoes total internal reflection at the prism–metal interface
and photons excite the electrons in the metal film. The wave
vector of these excited electrons at a specific angle of
incidence is equal to that of the surface plasmons, which
results in a total energy transfer. At this angle, the light beam is
Fig. 5 a Overview of the Kinobeads assay. Either lysates or cells are
treated with the compound (ligand or lead compound) over a range of
concentrations (top). Subsequently, proteins are captured on Kino-
beads. The in-solution ligand competes with the immobilized ligands
for ATP binding or related ligand binding sites of its targets (middle).
Bound proteins are digested with trypsin and each peptide pool is
labeled with iTRAQ reagent (not shown). All four samples are
combined and analyzed by MS. Each peptide gives rise to four
characteristic iTRAQ reporter signals (scaled to 100%) indicative of
the inhibitor concentration used (bottom left). For each peptide
detected, the decrease of signal intensity compared with the control
reflects competition by the in-solution ligand for its target (bottom
right). b Examples of competition binding curves calculated from
iTRAQ reporter signals. Binding of several known and novel targets
to Kinobeads depends on the addition of the ligands imatinib (blue
curves), dasatinib (green curves), and bosutinib (red curves) to K562
cell lysate. For each ligand, three independent quadruplexed experi-
ments (control plus three ligand concentrations each) were performed
in duplicate, and iTRAQ reporter signal data were combined to
display the dose response over nine concentrations. c Kinase-binding
profiles of the ABL ligands (kinase-inhibiting drugs) imatinib,
dasatinib, and bosutinib across a set of protein kinases simultaneously
identified from K562 cells. The bars indicate the IC50 values, defined
as the concentration of drug at which half-maximal competition of
binding of Kinobeads is observed. DMSO = dimethyl sulfoxide.
(Reprinted from Bantscheff et al. [92]. With permission)
R
Fig. 6 View of an exemplifying setup used for online affinity trapping
of proteins followed by in-solution online digestion and again trapping
on a solid-phase extraction (SPE) column prior to LC-MS. Proteins
are injected (1) onto an immunoaffinity chromatography column (2)
and nonbinders are eluted to the waste (W2; switching valve S2 is
therefore temporarily switched). The disruption buffer (3) elutes the
bound proteins by switching valve S1. A protease in solution present
in a cooled superloop (4) is mixed in continuously with help of an LC
pump (5). The digestion now takes place online in a thermostated
reaction coil (6) and the peptides formed are trapped on an SPE
column (7). After switching valve S2, the gradient LC pumps (8)
desalinate the trapped peptides and elute the peptides over the LC
column (9) to the mass spectrometer (10). Switching valve S3 and LC
pump 11 are used for reequilibration of the LC column
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no longer reflected. The biosensor mechanism depends on the
fact that the angle at which this happens depends on the
composition of the solution near the surface. Ligand binding
to an immobilized protein on the metal sensor changes the
wave vector of the surface plasmons and the angle of
incidence at which SPR occurs. As the technology only
allows analysis of binding events without identification
capabilities, SPR is sometimes combined with a mass
spectrometer in order to identify the binding partners.
Since the launch of commercially available SPR biosensors,
such as the Biacore [115], SPR has become an increasingly
prominent technology in drug discovery. Presently, multi-
plexed SPR biosensors enable the recording of multiple
binding experiments simultaneously [116]. In the Biacore and
most competing SPR biosensors, an analyte is infused onto a
chip with immobilized target protein and starts to bind until
all possible binding sites are occupied, or until equilibrium is
reached. Then, the chip is saturated or equilibrated. The speed
at which this happens depends on association and dissociation
rates of the complex, analogous to frontal affinity chroma-
tography [58]. Likewise, the resulting data and data process-
ing are analogous to those in frontal affinity chromatography.
In SPR, the change in signal depends on analyte concentra-
tion and molecular weight. This is why SPR bioassays are
especially suitable for the study of protein–protein interac-
tions, or other large molecules that bind to an immobilized
target protein or ligand.
Not surprisingly, the first major applications of SPR
biosensors were antibody–antigen interactions [117], the
study of DNA hybridization and dehybridization [118], and
some other macromolecular interactions. Additionally, SPR
has been coupled with MALDI time-of-flight MS in a
number of cases, in which the SPR chip was directly used
as the MALDI chip [119]. In this SPR-MALDI-based
analytical setup, different target proteins have been looked
at [20, 119, 120]. SPR-MS coupling has been used for a
few years and interesting articles on recent SPR-MS
method development include the work of Bouffartigues et
al. [121] on a high-throughput SPR–surface-enhanced laser
desorption ionization–MS method to identify protein bound
to DNA, and that of Marchesini et al. [122] on an online
coupling of an SPR method and a nano-LC system,
resulting in an online ESI interface between the SPR-LC
system and the mass spectrometer. An elegant solution for
semiquantitatively analyzing and identifying protein bind-
ers to small molecules is to immobilize the small molecules
on the chip, and subsequently measure the binding of the
target proteins followed by elution to LC-MS [123].
For measurement of binding kinetics (kon and koff) or
signaling events, besides SPR [124], also other technolo-
gies, such as total internal reflection fluorescence, can be
applied, but these are commonly performed without
compound identification by a parallel-placed mass spec-
trometer. In most cases, the use of MS is actually not
needed as the compounds analyzed are known and are pure
compounds. When unknown compounds are present in a
mixture, the mass spectrometer can be placed efficiently
after SPR technologies, then rendering the SPR more as an
affinity-selection method since the characteristic binding
kinetics information obtained by SPR is less useful for
(protein) mixtures when multiple unknown binders are
expected. However, the protein quantification capabilities
of SPR are powerful in combination with MS. Then the MS
data complement the SPR detection. The combination can
reveal intrinsic protein structural modifications that cannot
be analyzed by SPR detection alone.
Borch and Roepstorff described protocols for SPR-based
protein capture, elution, and robust sample preparation for
sensitive MS-based identification [125] and Nedelkov [126]
described protocols and know-how for efficient coupling of
SPR and MS. Similar to SPR-MALDI approaches, high-
resolution localized SPR sensors have also been used in
combination with MALDI and besides similar detection and
identification possibilities have the additional advantage of
showing fewer interferences from changes in the bulk
refractive index. In a typical case, this combination was used
by Anker at al. [127] to study amyloid β oligomers,
important players in Alzheimer’s disease.
In conclusion, SPR-MS is a highly specific tool for the
quantification and identification of proteins. It is efficient for
high molecular weight compounds, and therefore particularly
suitable for the study of protein–protein interactions and
proteins interacting with immobilized ligands.
Conclusions and perspectives
For the analysis of noncovalent protein complexes or
assemblies, advances in MS hardware and scientific
expertise have opened up new ways of investigation. Key
advantages of these so-called native MS approaches are the
speed of analysis and the potential for directly analyzing
complexes in solution. Although in vitro samples (e.g., cell
lysates) can in theory be studied directly, artificially
elevated concentrations of binding proteins have to be used
for a study and other potential (unknown) proteins present
under physiological conditions are omitted from the
experiment. An important advantage of native MS compared
with other structural biology methods is the significantly
smaller amount of sample required. It is essential to keep in
mind that all complexes are analyzed in the gas phase and not
under physiological conditions. Furthermore, method devel-
opment is crucial and can be elaborate. However, the results
obtained by studying protein–protein and protein–ligand
interactions most often do resemble the results obtained with
traditional biological/biochemical approaches. In fact, these
MS approaches are complementary to traditional methods in
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terms of data obtained. In many current cases, MS is the
primary analytical technique of choice because of conve-
nience, speed, and also its capability to study extremely large
and diverse protein assemblies. Evidently, it is not possible to
obtain high-resolution images including the shapes of protein
complexes. But new ion mobility capabilities prior to the MS
readout increasingly allow more detailed information on
protein complexes to be obtained.
Considerable progress has also been made in protein–
protein-interaction-based pull-down strategies followed by
MS analysis, and the field is rapidly expanding. The data
obtained require careful interpretation, because nonspecific
binding processes during the pull-down experiments may
introduce artifacts and thereby jeopardize the quality and
validity of the end results regarding the eventual protein
binding partners identified. Clearly, the pull-down part or
“protein fishing” process has to be optimized and validated
thoroughly prior to actual biological experiments. Further-
more, after protein complexes have been identified byMS, the
use of traditional biochemical approaches is encouraged to
confirm the MS-based results, followed by additional research
with other approaches for further characterization. As such,
MS provides an efficient means of screening for relevant
protein–protein or protein–ligand interactions to be character-
ized further in depth by more traditional technologies.
When using pull-down proteomics studies from a slightly
different angle, by pulling down drug target proteins via
immobilized lead compounds or ligands (e.g., on an affinity
column), the technology has opened up avenues to elaborate
pharmaceutical selectivity analysis of lead compounds. In
these methods, increasing concentrations of ligand added to
the drug targets studied (in whole cell lysates) prevent the drug
targets from binding to the immobilized ligand and thus
preclude them from subsequent MS-based detection. In this
way, many different drug targets and off-targets (antitargets)
are screened at once (such as protein kinases), where the
higher-affinity drug targets are displaced first and the lower-
affinity drug targets are displaced later. Consequently, the
technology allows inhibitory profiles to be analyzed for lead
compounds in whole panels of drug targets. In the future, this
might facilitate the vision of developing drugs that target
panels of disease-involved drug targets instead of the accepted
view of having one drug for one target. Perhaps, in the far
future, this technology will even aid in drug discovery
strategies leading to personalized medicines.
Finally, SPR is a very strong technology for the analysis of
protein–protein and protein–immobilized ligand interactions,
but is of less importance for the study of small ligands. The
combination of SPR andMS is a strong asset because it allows
the identification of the binding partners in complex mixtures.
However, one must bear in mind that one of the main
capabilities of SPR, the analysis of the binding kinetics of
single known binders, is lost when analyzing mixtures of
(unknown) proteins when it is coupled with MS. Then, SPR
can only be used for semiquantitation of all combined binders
to the SPR surface.
Open Access This article is distributed under the terms of the
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mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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